Van Beek Jeroen B's Form 4 filing
Kalaris Therapeutics, Inc. (KLRS) · filed Aug 17, 2022
- Accession no.
- 0000899243-22-029045
- Filed
- Aug 17, 2022
- Trade date
- Aug 16, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $129.4K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Van Beek Jeroen BCIK 0001743662 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | Common Stock | SSaleDisposed | −15,590 | $8.30F2 | −$129,397 | 386,363 | Direct | |
| Aug 16, 2022 | Common Stock | AGrant or awardAcquired | +15,000 | $0.00 | $0 | 401,363 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.12 to $8.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.